Why long-horizon innovation needs more than good ideas
An analysis of what Australian long-horizon research commercialisation requires, citing Gilmour Space, Cochlear and BluGlass as illustrations of patient capital and ecosystem support needs.
Company
Biotechnology industry organisation.
Every investor coverage indicates participated in a round AusBiotech raised.
Companies AusBiotech acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Rebekah Cassidy | CEO | Radium Capital, @AuManufacturing |
Stories naming AusBiotech. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
An analysis of what Australian long-horizon research commercialisation requires, citing Gilmour Space, Cochlear and BluGlass as illustrations of patient capital and ecosystem support needs.
Health technology governance veteran Sergio Duchini joins ANDHealth's board, adding capital markets and R&D commercialisation expertise to the digital health accelerator.
Roundup covering manufacturing placements by Sparc Technologies and Aurora Labs, Wellnex's planned London listing, an autonomous navy boat trial, a workplace fine, a software degree launch and AusBiotech's next CEO.
AusBiotech's release announces ChemGenex chief executive Greg Collier won the 2009 Chairman's Excellence Award for his contribution to Australian biotechnology, noting the company's US drug application for a leukemia medicine.